FDA Mixed up [RSABE / ABEL]
❝ I must confess that I never understood why the FDA statisticians (they are, really ) recommend the use of SAS Proc GLM or MIXED within their analysis of intra-subject contrasts for the two different designs within the scABE framework.
Agree. Not the slightest (!) idea.

❝ Since the contrasts (T-R or R1-R2) are analyzed via an model with sequence group as the solely effect (fixed) both SAS procedures will give exactly the same results AFAIK.
Yes.
❝ On the other hand the Proc Mixed code for unscaled ABE in case of the partial replicate crossover doesn't work in all cases as we had discussed here often.
Oh dear.
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- Replicate Design: Scaling FDA Ben 2012-10-23 11:32 [RSABE / ABEL]
- Maybe – but why? Helmut 2012-10-23 15:35
- Maybe – but why? Ben 2012-10-23 16:03
- Got it. Helmut 2012-10-23 16:23
- FDA Mixed up d_labes 2012-10-23 16:23
- FDA Mixed upHelmut 2012-10-23 16:34
- Maybe – but why? Ben 2012-10-27 17:04
- Maybe – but why? Helmut 2012-10-27 17:57
- Maybe – but why? Ben 2012-10-28 13:57
- Potvin (and beyond?) Helmut 2012-10-28 15:59
- Potvin (and beyond?) Ben 2012-11-01 10:17
- Potvin (and beyond?) Helmut 2012-10-28 15:59
- Maybe – but why? Ben 2012-10-28 13:57
- Maybe – but why? Helmut 2012-10-27 17:57
- Maybe – but why? Ben 2012-10-23 16:03
- Maybe – but why? Helmut 2012-10-23 15:35